Lymphoma Regression Induced by Ganciclovir in Mice Bearing a Herpes Thymidine Kinase Transgene
- 1 July 1990
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 1 (2), 125-134
- https://doi.org/10.1089/hum.1990.1.2-125
Abstract
The dose limitations imposed on cancer chemotherapeutic agents by their lack of selectivity can, in theory, be circumvented by a strategy entailing the prophylactic insertion into hosts of drug-sensitivity genes that are acquired or expressed in some but not all cells. This strategy predicts that neoplasms arising from drug-sensitive cells might be safely treatable with tumor-eradicative drug doses because the presence of a modicum of drug-insensitive stem cells will protect vital tissues from lethal depopulation. To test this prediction, lymphomas were induced with Abelson leukemia virus in mice bearing a herpes simplex virus thymidine kinase (HSV-TK) transgene selectively expressed in lymphoid cells. Of 12 transgenic mice treated with the HSV-TK-specific substrate ganciclovir (GCV), 11 exhibited complete tumor regressions; 5 of these mice remained tumor-free over observation periods that exceeded 100 days. Among the lymphomas that recurred, most appeared to represent mutant subpopulations that were GCV-insensitive because they had lost HSV-TK, implying that independent insertion of multiple HSV-TK gene copies might provide a means of preventing recurrences. The results of this study demonstrate that chemosensitivity genes can enhance the efficacy of treatment in hosts who subsequently develop a neoplasm. While the use of a germ-line gene insertion model precludes direct human application, the results also imply the merits of exploring an alternative version of the strategy in which somatic insertion of chemosensitivity genes in mosaic fashion is used prophylactically to enhance the prospect that a subsequent tumor will respond to therapy. Gene therapy is usually thought of as a treatment procedure that would supply a missing gene. But genes of all types can potentially be inserted into a patient's cells. Moolten et al. demonstrate how a suicide gene that had been inserted into a mouse in such a way that it would only function in lymphoid cells could be used later to kill malignant lymphoid cells in the mouse.Keywords
This publication has 19 references indexed in Scilit:
- Transgenic mice with inducible dwarfismNature, 1989
- Cell transformation and tumor induction by Abelson murine leukemia virus in the absence of helper virus.Proceedings of the National Academy of Sciences, 1987
- Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow.The Journal of Experimental Medicine, 1987
- The Molecular Genetics of CancerScience, 1987
- Inhibition of HSV-transformed murine cells by nucleoside analogs, 2′-NDG and 2′-nor-cGMP: Mechanisms of inhibition and reversal by exogenous NucleosidesVirology, 1985
- Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanineAntimicrobial Agents and Chemotherapy, 1983
- Inhibition of herpes simplex virus transformed and nontransformed cells by acycloguanosine: Mechanisms of uptake and toxicityVirology, 1981
- Gene transfer in intact animalsNature, 1980
- Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with Herpesvirus genetic informationVirology, 1980
- Anticellular Effects of 9-(2-Hydroxyethoxymethyl) Guanine Against Herpes Simplex Virus-transformed CellsJournal of General Virology, 1979